Loading...

NanoString Technologies, Inc.

NSTGNASDAQ
Healthcare
Medical - Instruments & Supplies
$0.11
$-0.06(-37.43%)

NanoString Technologies, Inc. (NSTG) Stock Overview

Explore NanoString Technologies, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.6/100

Key Financials

Market Cap5.1M
P/E Ratio-0.03
EPS (TTM)$-3.53
ROE-1.43%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.09

NSTG Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of NanoString Technologies, Inc. (NSTG) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.09.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.03 and a market capitalization of 5.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for NSTGStats details for NSTG are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NSTGAnalyst Recommendations details for NSTG are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.

CEO

R. Bradley Gray

Employees

550

Headquarters

530 Fairview Avenue North, Seattle, WA

Founded

2013

Frequently Asked Questions

;